Acute Pain
Feb 17, 2025
Vertex’s JOURNAVX: A Historic Milestone in Pain Treatment After a Long Dry Spell
A week after Purdue Pharma and the Sackler family agreed to a $7.4 billion settlement over lawsuits related to the opioid painkiller OxyContin, the FDA approved Vertex’s suzetrigine, marking the first novel mechanism for acute pain relief in over 20 years—potentially reshaping the treatment landscape. ...
Read More...
Feb 04, 2025
AstraZeneca Scraps £450M UK Vaccine Factory; FDA Approves First Non-Opioid Pain Reliever JOURNAVX in 20+ Years; Axsome’s SYMBRAVO Wins FDA Nod for Migraine; March Biosciences’ MB-105 Gains FDA Orphan Status for T-Cell Lymphoma; Saol’s SL1009 NDA Accepted for Pyruvate Dehydrogenase Complex Deficiency
AstraZeneca Scraps £450M Vaccine Factory in UK, Dealing a Blow to Reeves AstraZeneca has withdrawn its planned £450 million investment to expand a vaccine manufacturing facility in Liverpool, citing reduced financial support from the new Labour government. Initially announced in the previous Conservative governm...
Read More...
Oct 17, 2023
Novo Nordisk to Acquire Ocedurenone; FDA Awards Orphan Drug Designation to SLS009 in AML; FDA Approves Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma; Fast Track Designation to South Rampart Pharma’s SRP-001; TAGRISSO + Chemotherapy Granted Priority Review in the US; Fast Track Designation to SurVaxM for Glioblastoma
South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain On October 12, 2023, South Rampart Pharma, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track status to its drug candidate, SRP-001, intended for the management of acute pain. SRP-001 is a...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
